Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Benefits (Research Focus) Dual receptor agonism studied for simultaneous activation of GIP and GLP-1 receptors with imbalanced biased agonism Glycemic control research investigated for fasting glucose, HbA1c, and insulin sensitivity parameters in T2D models Body composition examined for fat-mass and lean-mass partitioning in obesity models Gastric emptying explored for delayed gastric transit and downstream satiety endpoints Long-acting profile C20 fatty diacid albumin-binding chemistry for extended half-life (~5 days) What Researchers Look At Receptor binding affinity and selectivity at GIPR vs GLP-1R cAMP and -arrestin recruitment in cell lines expressing each receptor subtype Food intake, body weight, and adipose-tissue change in DIO rodent models Gastric emptying time and gastrointestinal transit profiles Comparative pharmacology versus semaglutide, retatrutide, and other incretin analogs Quick Specs Form: Lyophilized white powder Net Peptide Content: 10 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: Tirzepatide Synonyms: LY3298176
Our programs focus on metabolic health, body composition tracking, and personalized nutrition guidance while helping patients build habits that support lasting results
You would have to take 0.5mg or 1mg, neither of which is what was prescribed
This finding is consistent with the hypothesis that incretin signalling at GLP-1R and GIPR functionally counterbalances the glucagonergic input under high-glucose conditions
Individual sensitivity to these mechanisms varies widely
If your vial has been frozen accidentally, do not use it
US$ 20.53
US$ 28.27
US$ 22.52
US$ 29.27
US$ 22.23
US$ 21.70
US$ 22.86
US$ 22.04
